LENZ Therapeutics, Inc. (NASDAQ:LENZ) saw its stock rise 6.1% in premarket trading following the release of its ...

When putting together your watch list, focus on stocks with an 80 or higher RS Rating. LENZ Therapeutics LENZ now meets that criteria, with a jump from 79 to 85 Friday. Please watch the video at ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

The FDA approved Vizz for the treatment of presbyopia in adults, according to a press release from Lenz ...

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 Provided by GlobeNewswire Mar 11, 2025, 12:00:00 PM ...

Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug application. Get the Strategy to Trade Pre-Fed Setups and Post-Fed ...

LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients ...